Actively Recruiting
Personalized Theratyping Trial
Led by George Solomon · Updated on 2026-02-02
20
Participants Needed
1
Research Sites
421 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
CONDITIONS
Official Title
Personalized Theratyping Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of CF
- Age 6 years or older
- CFTR mutation that may respond to approved correctors or potentiators as judged by study investigators
- Signed informed consent or assent
- Stable cystic fibrosis pulmonary regimen
You will not qualify if you...
- Lung exacerbation requiring antibiotics or steroids within 28 days before trial entry
- Current participation in another CFTR modulator study
- Active smoking within the past 6 months
- History of solid organ transplant
- Conditions preventing use of CFTR modulators such as advanced cirrhosis or end-stage renal disease
- Any condition that prevents participation as determined by the investigator
- Use of medications with significant drug interactions or other off-label CFTR modulator use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
Research Team
H
Heather Hathorne, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here